{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:43:35Z","timestamp":1793727815073,"version":"4.6.1"},"reference-count":214,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ekir.2025.11.029","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:12:27Z","timestamp":1764835947000},"page":"103705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation"],"prefix":"10.1016","volume":"11","author":[{"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Garred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.11.029_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.ekir.2025.11.029_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - Molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molimm.2020.10.015","article-title":"Complement-mediated kidney diseases","volume":"128","author":"Poppelaars","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","article-title":"The role of complement in kidney disease","volume":"19","author":"Petr","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ki.2012.407","article-title":"Bacterial infection-related glomerulonephritis in adults","volume":"83","author":"Nasr","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ki.2012.384","article-title":"Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement","volume":"83","author":"Sethi","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/20469047.2017.1369642","article-title":"Post-infectious glomerulonephritis","volume":"37","author":"Balasubramanian","year":"2017","journal-title":"Paediatr Int Child Health"},{"key":"10.1016\/j.ekir.2025.11.029_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ekir.2022.02.021","article-title":"The rational use of complement inhibitors in kidney diseases","volume":"7","author":"Fakhouri","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.11.029_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clim.2008.03.506","article-title":"Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis","volume":"128","author":"Slot","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2350-10-121","article-title":"Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis","volume":"10","author":"Carr","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib13","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1084\/jem.20072413","article-title":"Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake","volume":"205","author":"Willcocks","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00439-004-1092-z","article-title":"New genomic region for Wegener\u2019s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes","volume":"114","author":"Jagiello","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib15","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/art.38036","article-title":"Association of granulomatosis with polyangiitis (Wegener\u2019s) with HLA-DPB1\u221704 and SEMA6A gene variants: evidence from genome-wide analysis","volume":"65","author":"Xie","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.11.029_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/rheumatology\/kep057","article-title":"HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener\u2019s granulomatosis","volume":"48","author":"Stassen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.11.029_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib18","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1681\/ASN.2010101058","article-title":"DRB1\u221715 allele is a risk factor for PR3-ANCA disease in African Americans","volume":"22","author":"Cao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib19","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/art.22834","article-title":"HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome","volume":"56","author":"Vaglio","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.11.029_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1084\/jem.181.2.585","article-title":"A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells","volume":"181","author":"Kain","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib21","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM198806233182504","article-title":"Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis","volume":"318","author":"Falk","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib22","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V75.11.2263.2263","article-title":"Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3","volume":"75","author":"Jennette","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2025.11.029_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"Jozsi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2025.11.029_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2025.11.029_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trre.2009.06.002","article-title":"The role of antibodies in transplantation","volume":"23","author":"Chang","year":"2009","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.ekir.2025.11.029_bib28","article-title":"Antibody-mediated rejection in kidney transplantation: a review","volume":"2012","author":"Puttarajappa","year":"2012","journal-title":"J Transplant"},{"key":"10.1016\/j.ekir.2025.11.029_bib29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1681\/ASN.V641178","article-title":"Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome","volume":"6","author":"Kalluri","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.11.029_bib35","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13023-019-1237-8","article-title":"C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy","volume":"14","author":"Garam","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228101","article-title":"Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD","volume":"15","author":"Ibrahim","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.11.029_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib41","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1681\/ASN.2015010012","article-title":"Rare variants in the Complement Factor H-Related Protein 5 gene contribute to genetic susceptibility to IgA nephropathy","volume":"27","author":"Zhai","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib42","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.1997.361","article-title":"Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG","volume":"52","author":"Tomana","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.11.029_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6734","article-title":"Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy","volume":"9","author":"Nihei","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.ekir.2025.11.029_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.autrev.2017.11.024","article-title":"Genetics of immunoglobulin-A vasculitis (Henoch-Schonlein purpura): an updated review","volume":"17","author":"Lopez-Mejias","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.11.029_bib46","article-title":"IgA vasculitis update: epidemiology, pathogenesis, and biomarkers","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clim.2016.09.012","article-title":"Genetics of human lupus nephritis","volume":"185","author":"Iwamoto","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib48","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.ekir.2024.01.052","article-title":"Clinical relevance of anti-C3 and anti-C4 autoantibodies in lupus nephritis","volume":"9","author":"Vasilev","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.11.029_bib49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/15321819.2021.1895215","article-title":"High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with Lupus Nephritis","volume":"42","author":"Kianmehr","year":"2021","journal-title":"J Immunoassay Immunochem"},{"key":"10.1016\/j.ekir.2025.11.029_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103535","article-title":"A critical view on autoantibodies in lupus nephritis: concrete knowledge based on evidence","volume":"23","author":"Bruschi","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.11.029_bib51","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.42941","article-title":"Association of autoantibody concentrations and trajectories with lupus nephritis histologic features and treatment response","volume":"76","author":"Fava","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2025.11.029_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib53","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(79)92118-4","article-title":"Strong association between idiopathic membranous nephropathy and HLA-DRW3","volume":"2","author":"Klouda","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.11.029_bib55","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib56","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2025.11.029_bib57","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib58","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2215\/CJN.16631020","article-title":"Limited significance of antifactor H antibodies in patients with membranous nephropathy","volume":"16","author":"Sethi","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib59","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41581-025-00980-z","article-title":"Antigens in membranous nephropathy: discovery and clinical implications","volume":"21","author":"Sethi","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib60","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s11255-023-03831-7","article-title":"Evaluation of the significance of complement-related genes mutations in atypical postinfectious glomerulonephritis: a pilot study","volume":"56","author":"Xu","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib61","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2019080851","article-title":"Anti-factor B antibodies and acute postinfectious GN in children","volume":"31","author":"Chauvet","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clim.2008.04.005","article-title":"Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis","volume":"128","author":"Kozyro","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib63","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1073\/pnas.85.12.4516","article-title":"Renal autoimmune epitope of group A streptococci specified by M protein tetrapeptide Ile-Arg-Leu-Arg","volume":"85","author":"Kraus","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2025.11.029_bib64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2025.11.029_bib65","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ekir.2023.06.010","article-title":"Challenges in IgA nephropathy management: an era of complement inhibition","volume":"8","author":"Tesa\u0159","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.11.029_bib66","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.ekir.2025.11.029_bib67","doi-asserted-by":"crossref","first-page":"998","DOI":"10.4049\/jimmunol.2400185","article-title":"C1q\/MASP complexes-hybrid complexes of classical and lectin pathway proteins are found in the circulation","volume":"213","author":"Rosbjerg","year":"2024","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40120-021-00315-7","article-title":"ANCA-associated vasculitic neuropathies: a review","volume":"11","author":"Koike","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ekir.2025.11.029_bib70","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib71","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2025.11.029_bib72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical development of ANX005: a humanized anti-C1q Antibody for treatment of autoimmune and neurodegenerative diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.ekir.2025.11.029_bib73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib75","author":"Novartis"},{"key":"10.1016\/j.ekir.2025.11.029_bib76","author":"Novartis"},{"key":"10.1016\/j.ekir.2025.11.029_bib81","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib82","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1074\/mcp.M115.056473","article-title":"Structure of complement C3(H2O) revealed by quantitative cross-linking\/mass spectrometry and modeling","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ekir.2025.11.029_bib83","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature04005","article-title":"Structures of complement component C3 provide insights into the function and evolution of immunity","volume":"437","author":"Janssen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2025.11.029_bib84","doi-asserted-by":"crossref","first-page":"35725","DOI":"10.1074\/jbc.M111.263418","article-title":"Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein","volume":"286","author":"Hourcade","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ekir.2025.11.029_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/srep31877","article-title":"MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked","volume":"6","author":"Dobo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.11.029_bib86","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ekir.2025.11.029_bib87","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.addr.2011.05.010","article-title":"Advances in assay of complement function and activation","volume":"63","author":"Harboe","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ekir.2025.11.029_bib88","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fimmu.2019.01308","article-title":"Complement nomenclature-deconvoluted","volume":"10","author":"Bohlson","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152707","article-title":"Complement and coagulation crosstalk - Factor H in the spotlight","volume":"228","author":"Heurich","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.ekir.2025.11.029_bib90","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.4049\/jimmunol.162.7.4018","article-title":"Human T cells express the C5a receptor and are chemoattracted to C5a","volume":"162","author":"Nataf","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib91","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneph.2014.114","article-title":"Inflammatory processes in renal fibrosis","volume":"10","author":"Meng","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2025.11.029_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ki.1994.247","article-title":"Localization of the complement regulatory proteins in the normal human kidney","volume":"46","author":"Ichida","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae215","article-title":"Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases","volume":"17","author":"Alkaff","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.11.029_bib95","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4049\/jimmunol.178.1.352","article-title":"Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay","volume":"178","author":"Harris","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1135490","article-title":"The human factor H protein family - an update","volume":"15","author":"Sandor","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib97","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1038\/s41467-019-10766-0","article-title":"Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies","volume":"10","author":"Irmscher","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2025.11.029_bib98","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2025.11.029_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina","year":"2019","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2025.11.029_bib100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.RV17026","article-title":"Pathogenesis of atypical hemolytic uremic syndrome","volume":"26","author":"Yoshida","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ekir.2025.11.029_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib102","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000442323","article-title":"Overview of the pathogenesis of ANCA-associated vasculitis","volume":"1","author":"Xiao","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2025.11.029_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2025.11.029_bib104","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The role of complement in IgA nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.11.029_bib106","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2025.11.029_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1229806","article-title":"Unleashing the power of complement activation: unraveling renal damage in human anti-glomerular basement membrane disease","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib108","article-title":"The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.11.029_bib109","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.3.5882.668","article-title":"Plasma C3 and C4 concentrations in management of glomerulonephritis","volume":"3","author":"Cameron","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.ekir.2025.11.029_bib110","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.11.029_bib111","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2020.05.053","article-title":"Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties","volume":"98","author":"Fakhouri","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib112","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib113","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/ndt\/gfs288","article-title":"Idiopathic membranoproliferative glomerulonephritis: does it exist?","volume":"27","author":"Fervenza","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.11.029_bib114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fmed.2017.00066","article-title":"Complement in kidney transplantation","volume":"4","author":"Cernoch","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2025.11.029_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152396","article-title":"Complement activation and kidney transplantation; a complex relationship","volume":"228","author":"Gibson","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.ekir.2025.11.029_bib116","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5500\/wjt.v6.i4.632","article-title":"Complement related kidney diseases: recurrence after transplantation","volume":"6","author":"Salvadori","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.ekir.2025.11.029_bib117","first-page":"52","article-title":"Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature","volume":"1","author":"Alasfar","year":"2014","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2025.11.029_bib118","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf134","article-title":"Kidney transplant in patients with C3 glomerulopathy","volume":"18","author":"Attieh","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.11.029_bib119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2014.217","article-title":"Histopathology of MPGN and C3 glomerulopathies","volume":"11","author":"Cook","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1081942","article-title":"Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/antib12020040","article-title":"IgA nephropathy: current treatment and new insights","volume":"12","author":"Petrou","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ekir.2025.11.029_bib123","first-page":"1","article-title":"Extracapillary proliferation in IgA nephropathy; recent findings and new ideas","volume":"4","author":"Nasri","year":"2015","journal-title":"J Nephropathol"},{"key":"10.1016\/j.ekir.2025.11.029_bib124","article-title":"Risk stratification and long-term kidney survival in IgA nephropathy with particular emphasis on Oxford classification; A narrative review","volume":"11","author":"Hechanova","year":"2022","journal-title":"J Nephropathol"},{"key":"10.1016\/j.ekir.2025.11.029_bib125","series-title":"Systemic Lupus Erythematosus","first-page":"389","article-title":"Chapter 43 - The pathology of lupus nephritis","author":"Stillman","year":"2021"},{"key":"10.1016\/j.ekir.2025.11.029_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.724186","article-title":"Crescentic glomerulonephritis: pathogenesis and therapeutic potential of human amniotic stem cells","volume":"12","author":"Al Mushafi","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.ekir.2025.11.029_bib127","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib128","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/md.0b013e318161b0fc","article-title":"Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature","volume":"87","author":"Nasr","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2025.11.029_bib130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ckj\/sfw032","article-title":"Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy","volume":"9","author":"Khalighi","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.11.029_bib131","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.transproceed.2011.04.023","article-title":"Acute antibody-mediated rejection of renal transplant associated with cellular crescents: first case report","volume":"43","author":"Modelli de Andrade","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2025.11.029_bib132","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13722","article-title":"Antibody-mediated rejection with the presence of glomerular crescents in a pediatric kidney transplant recipient: a case report","volume":"24","author":"Karava","year":"2020","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.ekir.2025.11.029_bib133","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib134","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","article-title":"Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"91","author":"Bellur","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib136","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib137","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41379-019-0259-z","article-title":"Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis","volume":"32","author":"Chua","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ekir.2025.11.029_bib138","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2019.03.416","article-title":"Microangiopathic lesions in IgA nephropathy: a cohort study","volume":"74","author":"Cai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib139","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib140","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1159\/000527166","article-title":"Baseline clinical characteristics and complement biomarkers of patients with C3 glomerulopathy enrolled in two phase 2 studies investigating the factor D inhibitor danicopan","volume":"53","author":"Podos","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cei.12961","article-title":"Targeting C3a\/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice","volume":"189","author":"Zhang","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib142","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.1987.101","article-title":"Complement activation in IgA nephropathy","volume":"31","author":"Wyatt","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib143","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0272-6386(88)80042-8","article-title":"Activation of complement in IgA nephropathy","volume":"12","author":"Wyatt","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib144","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","article-title":"Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis","volume":"29","author":"Xing","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib146","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib147","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"Supplement_2","key":"10.1016\/j.ekir.2025.11.029_bib148","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/ndt\/gfad163","article-title":"Circulating alternative pathway complement cleavage factor Bb is associated with vascular lesions and outcomes in IgA nephropathy","volume":"38","author":"Stefan","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.11.029_bib149","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B","volume":"164","author":"Watanabe","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1523-1755.2004.00371.x","article-title":"Effects of complement factor D deficiency on the renal disease of MRL\/lpr mice","volume":"65","author":"Elliott","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib151","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-015-0656-8","article-title":"Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis","volume":"17","author":"Chen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2025.11.029_bib152","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib153","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.kint.2016.02.036","article-title":"Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury","volume":"90","author":"Laskowski","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib154","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor h-related protein-5 (FHR5) deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.11.029_bib155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib156","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/bmj.3.5875.326","article-title":"Glomerular deposition of properdin in Henoch-Schonlein syndrome and idiopathic focal nephritis","volume":"3","author":"Evans","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.ekir.2025.11.029_bib157","first-page":"217","article-title":"Deposition of C4-binding protein and beta 1H globulin in kidneys of patients with IgA nephropathy","volume":"6","author":"Tomino","year":"1981","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib158","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.1987.72","article-title":"Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis","volume":"31","author":"Rauterberg","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib159","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000184350","article-title":"Composition of mesangial deposits in IgA nephropathy: complement factors","volume":"46","author":"Bene","year":"1987","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2025.11.029_bib160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.nefro.2016.11.019","article-title":"Study of the variables associated with local complement activation in IgA nephropathy","volume":"37","author":"Segarra-Medrano","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.ekir.2025.11.029_bib161","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1086\/318203","article-title":"Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition","volume":"68","author":"Richards","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib162","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/318201","article-title":"Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome","volume":"68","author":"Perez-Caballero","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ekir.2025.11.029_bib163","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains","volume":"204","author":"Pickering","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib164","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1681\/ASN.2015030295","article-title":"Partial complement factor H deficiency associates with C3 glomerulopathy and thrombotic microangiopathy","volume":"27","author":"Vernon","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib165","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1172\/JCI99296","article-title":"Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice","volume":"129","author":"Smith-Jackson","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.11.029_bib166","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1681\/ASN.2015040348","article-title":"A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H","volume":"27","author":"Chauvet","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib167","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation","volume":"120","author":"Martinez-Barricarte","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.11.029_bib168","author":"Calliditas Therapeutics"},{"key":"10.1016\/j.ekir.2025.11.029_bib169","author":"Calliditas Therapeutics"},{"key":"10.1016\/j.ekir.2025.11.029_bib170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.11.029_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42729","article-title":"Targeted-release budesonide: a comprehensive review on its potential in IgA nephropathy","volume":"11","author":"Qi","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.ekir.2025.11.029_bib172","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib173","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib174","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib175","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2215\/CJN.12991117","article-title":"Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls","volume":"13","author":"Ponticelli","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib176","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib177","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib178","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib179","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib180","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib181","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib182","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2025.11.029_bib183","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib184","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.11.029_bib185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib186","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib187","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib188","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.11.029_bib196","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12882-023-03058-9","article-title":"Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study","volume":"24","author":"Welte","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib197","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2025.11.029_bib198","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.3390\/ijms25179477","article-title":"Navigating the complement pathway to optimize PNH treatment with pegcetacoplan and other currently approved complement inhibitors","volume":"25","author":"Hillmen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2025.11.029_bib199","author":"Cross"},{"key":"10.1016\/j.ekir.2025.11.029_bib202","article-title":"A phase 3, randomized, placebo-controlled, double-blinded, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT05067127"},{"key":"10.1016\/j.ekir.2025.11.029_bib203","first-page":"10","volume":"35","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib204","series-title":"Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy","author":"Fakhouri","year":"2025"},{"key":"10.1016\/j.ekir.2025.11.029_bib206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.11.029_bib207","doi-asserted-by":"crossref","first-page":"SA","DOI":"10.1681\/ASN.20245wvz1j0d","article-title":"Pegcetacoplan for post-transplant recurrent C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) in NOBLE: 52-week patient evolution","volume":"35","author":"Java","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib210","series-title":"Targeting complement factor B with siRNA: concept to clinic","year":"2024"},{"key":"10.1016\/j.ekir.2025.11.029_bib213","article-title":"HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: a first-in-human, phase 1 trial","author":"Xu","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib214","article-title":"Multicenter, randomized, double-blind, parallel, placebo-controlled phase III clinical trial, to evaluate the efficacy and safety of HRS-5965 capsule in primary IgA nephropathy","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT07014826"},{"key":"10.1016\/j.ekir.2025.11.029_bib220","series-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy: results from the phase 3 APPEAR-C3G trial","author":"Kavanagh","year":"2024"},{"key":"10.1016\/j.ekir.2025.11.029_bib221","first-page":"SA","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study","volume":"33","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib225","article-title":"A multicenter, single arm, open label biopsy study to evaluate structural and functional changes in kidneys of adult patients with IgA nephropathy receiving iptacopan on top of supportive care","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT06797518"},{"key":"10.1016\/j.ekir.2025.11.029_bib226","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib229","article-title":"A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of MY008211A in subjects with primary immunoglobulin A nephropathy (IgAN)","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT06687174"},{"key":"10.1016\/j.ekir.2025.11.029_bib230","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of NTQ5082 capsules in the treatment of patients with primary IgA nephropathy","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT06982040"},{"key":"10.1016\/j.ekir.2025.11.029_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152876","article-title":"Inhibiting the alternative pathway of complement by reducing systemic complement factor B: randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen","volume":"230","author":"McCaleb","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.ekir.2025.11.029_bib239","doi-asserted-by":"crossref","first-page":"TH","DOI":"10.1681\/ASN.2024m9vbe9km","article-title":"Phase II results of an investigational RNA therapeutic to complement factor B, IONIS-FB-LRx, for treatment of IgA nephropathy","volume":"35","author":"Barbour","year":"2024","journal-title":"J Am Soc of Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib240","series-title":"Design and characterization of KP104, a bifunctional anti-C5 mAb and FH1-5 fusion protein that synergistically inhibits alternative and terminal pathways of complement activation","author":"Gullipalli","year":"2022"},{"key":"10.1016\/j.ekir.2025.11.029_bib242","series-title":"OMS906, a novel alternative pathway MASP-3 inhibitor, improved hematologic parameters in patients with PNH and suboptimal response to ravulizumab treatment: phase 2 dose-finding study interim results","author":"Griffin","year":"2024"},{"key":"10.1016\/j.ekir.2025.11.029_bib244","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1537974","article-title":"Factor B as a therapeutic target for the treatment of complement-mediated diseases","volume":"16","author":"Kavanagh","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib245","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.4049\/jimmunol.166.10.6341","article-title":"Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models","volume":"166","author":"Ames","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2025.11.029_bib246","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib247","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2180508","article-title":"Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies","volume":"2017","author":"Rudnicki","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib248","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 Trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.11.029_bib250","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a Phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib251","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.11.029_bib253","first-page":"10","article-title":"Results from longer follow-up with povetacicept, an enhanced dual BAFF\/APRIL antagonist, in IgA nephropathy (RUBY-3 study)","volume":"35","author":"Madan","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.11.029_bib254","first-page":"WCN24","article-title":"Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoantibody-associated glomerulonephritis","volume":"9","author":"Tumlin","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:35:41Z","timestamp":1773963341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925007168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":214,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2468024925007168"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.11.029","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103705"}}